瑞芬太尼的心血管副作用机制与临床意义  

Cardiovascular side effects mechanism of remifentanil and clinical significance

作　　者：程文杰[1] 徐桂萍[1] 

机构地区：[1]石河子大学医学院,832000

出　　处：《国际麻醉学与复苏杂志》2013年第4期324-326,共3页International Journal of Anesthesiology and Resuscitation

摘　　要：背景瑞芬太尼是一种新型μ阿片受体激动药，其可有效地抑制心血管应激反应，但随着临床上应用的增多，其引起心动过缓和血压降低的副作用的报道也日益增多。目的综述目前瑞芬太尼对心血管作用机制的研究进展，为临床和基础更好地开展对该药的研究提供理论依据。内容从5个方面综述瑞芬太尼引起心动过缓，血压降低的机制。趋向目前对瑞芬太尼降低血压和心率（HR）的确切机制尚未完全清楚，实验方法上可应用电生理方法对其机制进行下一步研究。Background Remifentanil is a new type of μ opioid receptor agonist, which can effectively restrain the cardiovascular stress response. With the increasing clinical application, the reports that remifentanil causes bradycardia and hypotension are increasing. Objective This review on the mechanism of remifentanil on cardiovascular would provide theory support for further clinical and basic research. Content This review is to illustrate the mechanism of bradycardia and hypotension caused by remifentanil from five aspects. Trend So far, the mechanism of remifentanil causes bradycardia and hypotension is not entirely clear, and electrophysiology could be applied for further research.

关 键 词：瑞芬太尼 心血管作用机制 麻醉 

分 类 号：R614[医药卫生—麻醉学] R9[医药卫生—外科学]